Brii Biosciences Limited announced that Mr. Yongqing Luo tendered his resignation letter to resign as an executive Director, the President and General Manager, Greater China of the Company, and the chief executive officer of TSB Therapeutics Ltd. (Beijing) Co. Limited, all with effect from September 15, 2022, in order to pursue other opportunities. The Board announced that Dr. Ankang Li has been appointed as an executive Director with effect from September 30, 2022 in addition to his existing positions in the Company.

Following the appointment of Dr. Li as an executive Director, he has also been appointed as the chairman of the strategy committee of the Board with effect from September 30, 2022. Dr. Li, aged 44, has been appointed as an executive Director with such appointment to take effect from September 30, 2022 and as the chief executive officer of TSB Therapeutics with such appointment to take effect from September 16, 2022. He has been serving as the joint company secretary of the Company since April 8, 2021, and the chief financial and strategy officer of the Company since January 1, 2022, responsible for overseeing financial, accounting, legal, intellectual property, corporate development, procurement, investor relations and communication on matters of the Group.

He was the chief financial officer of the Company from September 1, 2020 to December 31, 2021. Dr. Li has more than ten years of experience in investment banking, business development, legal transaction and biomedical research. Prior to joining the Group, he was the chief financial officer of Terns Pharmaceuticals Inc., a clinical-stage biopharmaceutical company listed on NASDAQ Stock Exchange in the United States, and he was responsible for overseeing financial operation from June 2019 to August 2020.

He was an executive director within the corporate finance department division of Goldman Sachs, an investment bank, and he was responsible for providing financial advisory services from January 2018 to June 2019. He was a director of the business development department of MSD R&D (China) Co. Ltd., a China subsidiary of a global pharmaceutical company Merck Sharp & Dohme Corporation, and he was responsible for overseeing business development and licensing transactions of MSD Asia Pacific Innovation Hub from September 2016 to December 2017.

Dr. Li obtained his Bachelor of Science in Biochemistry from Fudan University in China in July 1999, a Master of Science in Biological Sciences from National University of Singapore in Singapore in October 2002, a Ph.D. in Biomedical Sciences from Baylor College of Medicine in the United States in June 2007 and a Juris Doctor degree from The University of Chicago Law School in the United States in June 2012. Dr. Li was also admitted to the New York Bar in January 2013 and was qualified as a Chartered Financial Analyst of the CFA Institute in August 2016. The Board announced that the following change in composition of the Strategy Committee with effect from September 30, 2022: Following the appointment of Dr. Li as an executive Director, he has also been appointed as the chairman of the Strategy Committee; Dr. Taiyin Yang, an independent non-executive Director, has also been appointed as a member of the Strategy Committee; and Dr. Zhi Hong, an executive Director and the chairman of the Board, has ceased to be the chairman of the Strategy Committee.

The Board announced the appointments of Dr. Qing Zhu as the Head of China Research and Development of the Company with effect from October 1, 2022 in addition to her existing positions in the Company, and Mr. Rico Liang as the Senior Vice President and General Manager, Greater China of the Company with effect from September 16, 2022. Dr. Zhu has been appointed as the Head of China R&D with such appointment to take effect from October 1, 2022. She has been serving as the Senior Vice President of the Company since July 16, 2020, responsible for research and development of biotherapeutics.

She was the Vice President of the Company from April 2, 2018 to July 15, 2020. Prior to joining the Group, Dr. Zhu held several positions in MedImmune, LLC (a subsidiary of Astrazeneca plc, which is a pharmaceutical company listed on London Stock Exchange in the United Kingdom and New York Stock Exchange in the United States from August 2007 to March 2018 and her last position therein was director and head of virology group and she was responsible for research and development of antiviral programs. Before that, she was a scientist in Novartis Pharmaceuticals Corporation, a pharmaceutical company in the United States, and she was responsible for translational research from April 2006. She was a scientist in Chiron Corporation, a biotech company in the United States, and she was responsible for leading research projects from April 2004 to April 2006.

She was a postdoctoral associate in Fox Chase Cancer Center, a research institute in the United States, and she completed postdoctoral training from May 2001 to April 2004. Dr. Zhu obtained her Bachelor of Science in Microbiology from ShanXi University in China in August 1989 and a Ph.D. in Molecular and Cell Biology Program from University of Maryland in the United States in July 2000. Mr. Liang was promoted and has been appointed as the Senior Vice President and General Manager, Greater China of the Company with such appointment to take effect from September 16, 2022.

He was the Vice President, Scientific and Medical Affairs of the Company from March 2021 to September 15, 2022 and the Head of Clinical Operation of the Company from January 2022 to September 15, 2022, responsible for leading external scientific engagements with key opinion leaders, medical associations and patient communities to facilitate trial execution and therapy launch preparation. Prior to joining the Group, Mr. Liang held several positions in Gilead China from February 2017 to February 2021, including the head of marketing, the head of human immunodeficiency virus sales and the executive marketing director, and he was responsible for commercial strategy design and implementation and leading marketing team to successfully deliver launches for innovative treatments. He was the senior marketing director of AbbVie Inc. China from May 2016 to February 2017, and he was responsible for building out hepatitis C virus marketing team and developing its portfolio strategy.

He was the marketing director of Roche from July 2013 to May 2016, and he was responsible for leading several marketing programs to turn around Pegasys business. Mr. Liang obtained his Bachelor of Medicine from Capital University of Medical Science in China in July 1991 and a Master of Commerce in Marketing from Macquarie University in Australia in February 2004.